ArticleACS omega2026
Small Molecule Cancer Drugs as Dual-Responsive, Dynamic-Covalent Cross-Linkers for PEG Hydrogels.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A dual-responsive hydrogel platform in which the anticancer drug doxorubicin (DOX) functions both as a therapeutic payload and as a dynamic covalent cross-linker is presented. While hydrogels are widely explored for controlled drug delivery, decoupling network remodeling from drug release remains challenging. To address this, I engineered bifunctional DOX derivatives incorporating two orthogonal, stimulus-cleavable linkages: a pH-labile oxime bond at the DOX keto group and a reductively cleavable, self-immolative disulfide linker attached via a stable carbamate at the daunosamine amine. These DOX cross-linkers were conjugated to multiarm poly-(ethylene glycol) (PEG) and assembled into hydrogels through dynamic-covalent oxime formation. The resulting networks were stable under physiological conditions but underwent pronounced reorganization upon acidic or reductive stimulation, leading to gel dissolution without significant drug release. In contrast, sequential application of both stimuli triggered quantitative release of native DOX. This hierarchical response enables independent control over network architecture and drug activation and establishes small-molecule chemotherapeutics as functional, dual-responsive cross-linkers for programmable hydrogel drug depots.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.